178 related articles for article (PubMed ID: 34764813)
1. Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α - benralizumab.
Kosałka-Węgiel J; Milewski M; Siwiec A; Strach M; Ochrem B; Korkosz M
Cent Eur J Immunol; 2021; 46(3):395-397. PubMed ID: 34764813
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab.
Fujii K; Takahashi H; Hayakawa N; Iwasaki Y
Respirol Case Rep; 2020 Nov; 8(8):e00665. PubMed ID: 33005423
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab for
Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
6. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
9. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
12. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
17. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
[TBL] [Abstract][Full Text] [Related]
18. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
19. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
20. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
